Post-approval studies (Phase 4)Study completedNCT01988662
What this trial is testing
UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
Who this might be right for
Neovacular Age-related Macular Degeneration
Novartis Pharmaceuticals 205